Literature DB >> 9697721

Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

C F Perno1, F M Newcomb, D A Davis, S Aquaro, R W Humphrey, R Caliò, R Yarchoan.   

Abstract

The activity of three human immunodeficiency virus (HIV) protease inhibitors was investigated in human primary monocytes/macrophages (M/M) chronically infected by HIV-1. Saquinavir, KNI-272, and ritonavir inhibited the replication of HIV-1 in vitro, with EC50s of approximately 0.5-3.3 microM. However, only partial inhibition was achievable, even at the highest concentrations tested. Also, the activity of these drugs in chronically infected M/M was approximately 7- to 26-fold lower than in acutely infected M/M and approximately 2- to 10-fold lower than in chronically infected H9 lymphocytes. When protease inhibitors were removed from cultures of chronically infected M/M, production of virus rapidly returned to the levels found in untreated M/M. Therefore, relatively high concentrations of protease inhibitors are required to suppress HIV-1 production in chronically infected macrophages, and such cells may be a vulnerable point for the escape of virus in patients taking these drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697721     DOI: 10.1086/515642

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  51 in total

Review 1.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Authors:  Martha Stefanidou; Carolina Herrera; Naomi Armanasco; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

3.  Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages.

Authors:  Mengyao Jin; Priyanka Arya; Kalpeshkumar Patel; Bhupendra Singh; Peter S Silverstein; Hari K Bhat; Anil Kumar; Santosh Kumar
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

4.  Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.

Authors:  Tuofu Zhu; David Muthui; Sarah Holte; David Nickle; Feng Feng; Scott Brodie; Yon Hwangbo; James I Mullins; Lawrence Corey
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 5.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

6.  Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.

Authors:  R R Speck; C Flexner; C J Tian; X F Yu
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.

Authors:  Jennifer A Fulcher; Yon Hwangbo; Rafael Zioni; David Nickle; Xudong Lin; Laura Heath; James I Mullins; Lawrence Corey; Tuofu Zhu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 8.  Cellular reservoirs of HIV-1 and their role in viral persistence.

Authors:  Aikaterini Alexaki; Yujie Liu; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

Review 9.  Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.

Authors:  Valentin Le Douce; Georges Herbein; Olivier Rohr; Christian Schwartz
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

10.  Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.

Authors:  Laura E Jones; Alan S Perelson
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.